Pamelor is a tricyclic antidepressant (TCA, tricyclic antidepressants) of the second generation. It is used in the treatment of some major depressive disorder and nocturnal enuresis (bedwetting) in children. In addition, the drug is sometimes used for the treatment of chronic diseases such as chronic fatigue syndrome, chronic pain and migraine, and the lability in certain neurological diseases.
An antidepressant means, which selectively inhibits the reuptake of serotonin (5-HT) in the central nervous system, enhances serotonergic transmission in the CNS. Used to treat depressions of various etiologies (including anxious, reactive, recurrent, atypical and post-psychotic, depressive episodes of bipolar disorder, dysthymia, depression on the background of schizophrenia, organic CNS diseases and alcoholism).
Enhances the protective mechanisms of the gastric mucosa by increasing the formation of gastric mucus and of glycoproteins in it, as well as stimulation of bicarbonate secretion and endogenous Pg synthesis in it, promotes healing of its injuries (including scarring of stress ulcers), and the cessation of gastrointestinal bleeding. The list of indications includes: gastric ulcer and duodenal ulcer, hyperacidity of gastric juice, heartburn (associated with hyperchlorhydria), symptomatic and stress ulcers of the gastrointestinal tract.
Blocker of H1-histamine receptors, also expresses antimuscarinic and antiserotonin activity. Anti-allergic effect is most vivid in respect of itching dermatoses. Used symptomatically during allergic reactions.
The drug dilates coronary vessels (mostly arterioles) and causes a significant increase in volumetric blood flow velocity. Increases the content of oxygen in venous blood of coronary sinus and its absorption by myocardium. Promotes the development of collateral coronary circulation, reduction in a systemic vascular resistance, improves microcirculation, has angioprotective action.
Phenergan is an antiallergic, topical anesthetic, antihistamine, antipruritic, antiemetic, hypnotic, sedative on the basis of Prometnazine.
Pirfenex shows anti- fibrosing and anti-inflammatory properties in many systems in vitro and in animal models of pulmonary fibrosis (the fibrosis induced by bleomycin and transplantation). Assigned to adults suffering the idiopatic pulmonary fibrosis.
Plavix is an antiplatelet drug; specific and active inhibitor of platelet aggregation; has a coronary-dilating effect. The use of Plavix is indicated for the prevention of atherothrombotic complications in adult patients with myocardial infarction in adult patients with an acute coronary syndrome. The drug is also indicated to prevent atherothrombotic and thromboembolic complications, including a stroke, atrial fibrillation in patients with atrial fibrillation, who have at least one risk factor for vascular complications and who cannot take indirect anticoagulants and have a low risk of bleeding.
A selective calcium channel blockers; a derivative of dihydropyridine; has a vasodilating, antihypertensive, antianginal effect. Has a high selective activity against smooth muscle of the arterioles. Prescribed to the patients with hypertension, angina pectoris (voltage, vasospastic, unstable with the ineffectiveness of beta-blockers and nitrates), Raynaud's syndrome (as a symptomatic drug).
A nonsteroidal anti-inflammatory drug that has anti-inflammatory, analgesic, antipyretic action. Prescribed for inflammatory diseases of the musculoskeletal system (rheumatoid, gouty arthritis, arthritis, ankylosing spondylitis), pain syndrome (ossalgia, neuralgia, myalgia, arthralgia, sciatica, headache, dental pain, childbirth), for orthopedic surgery, cancer, algodismenorrhea, febrile syndrome.
The oral hypoglycemic agent, which stimulates insulin release from functioning beta cells of the pancreas. Used for the treatment of diabetes mellitus type 2 under the ineffectiveness of diet, weight loss and physical activity.
An antiaggregant, used for the prevention of thrombotic complications in patients with acute coronary syndrome (ACS), who are planned to undergo percutaneous coronary angioplasty and for prevention of stent thrombosis in acute coronary syndromes. The medicine is a receptor antagonist of P2Y12class to adenosine diphosphate (ADP), and consequently inhibits the activation and aggregation of platelets. Since platelets are involved in the development of atherosclerosis complications, the inhibition of platelet function may lead to a decrease in the frequency of cardiovascular complications.
A lipid-lowering agent. Reversibly inhibits HMG-COA reductase, inhibits the cholesterol synthesis at the stage of mevinolinic acid and moderately reduces its intracellular concentration. The indications for the drug use include: primary hypercholesterolemia mainly of IIa and IIb types, under the ineffective diet treatment in patients with increased risk of coronary atherosclerosis, hypercholesterolemia combined with hypertriglyceridemia; prevention of coronary artery disease. The drug decreases the risk of myocardial infarction, the need for revascularization of the myocardium, deaths from cardiovascular system diseases.
An oral hypoglycemic means, which inhibiting the intestinal alpha-glycosidase, reduces the enzymatic conversion of di-, oligo - and polysaccharides to mono-saccharides, thereby reducing the absorption of glucose from the intestine and postprandial hyperglycemia. It is used to treat diabetes, of type 2 under the ineffective diet, the course of which shall not be less than 6 months, type 1diabetes within the combination therapy.
Prednisolone is a synthetic analogue of the adrenal cortex secreted by the hormones cortisone and hydrocortisone. Unlike cortisone and hydrocortisone, prednisolone does not cause a noticeable delay in sodium and water, and only slightly increases the release of potassium. The drug has a pronounced anti-inflammatory, antiallergic, anti exudative, anti-shock, antitoxic effect.